Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes

Yoshinobu Matsuo, Hans G. Drexler, Akira Harashima, Ayumi Okochi, Kensuke Kojima, Shoji Asakura, Mitsune Tanimoto, Kunzo Orita

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The two acute myelomonocytic leukemia sister cell lines MOLM-17 and MOLM-18 and the Epstein-Barr-virus positive non-malignant B-lymphoblastoid cell lines (B-LCLs) B422 and B423 were established from the bone marrow sample of a 60-year-old Japanese male in the advanced leukemic phase of refractory anemia with excess of blasts, a subtype of myelodysplastic syndromes (MDS). MOLM-17/-18 are proliferatively responsive to the growth factors present in the culture supernatant of the 5637 cell line. The B-LCLs are constitutively growth factor-independent. MOLM-17 and B422 were established at eight months after the initial diagnosis, while MOLM-18 and B423 were derived from a sample one month later. Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative. MOLM-17/-18 showed immunomarker profiles typical of the myelomonocytic lineage. The karyotype analysis of MOLM-17/-18 revealed various non-random numerical and structural abnormalities including del(5)(q?), -7, der(11)add(11)(p11.2)add(11)(q23), add(17)(p11.2), add(18)(p11.2), -20, -22 as common aberrations. Treatment with tumor necrosis factor-α induced pronounced cellular differentiation of both cell lines into macrophage-like cells. The overall profile of MOLM-17/-18 based on their extensive immunological, cytogenetic and functional characterization suggests that these cell lines together with the paired B-LCLs B422 and B423 may represent scientifically significant in vitro models which could facilitate investigations into the pathobiology of MDS.

Original languageEnglish
Pages (from-to)701-710
Number of pages10
JournalLeukemia Research
Volume29
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Myelodysplastic Syndromes
Myeloid Cells
Acute Myeloid Leukemia
Cell Line
DNA Nucleotidylexotransferase
Intercellular Signaling Peptides and Proteins
Leukemia
Leukemia, Myelomonocytic, Acute
Refractory Anemia with Excess of Blasts
Immunophenotyping
Human Herpesvirus 4
Karyotype
Cytogenetics
Siblings
Tumor Necrosis Factor-alpha
Bone Marrow
Macrophages

Keywords

  • AML
  • Cell line
  • Differentiation
  • Leukemia
  • MDS
  • TNF-α

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Matsuo, Y., Drexler, H. G., Harashima, A., Okochi, A., Kojima, K., Asakura, S., ... Orita, K. (2005). Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. Leukemia Research, 29(6), 701-710. https://doi.org/10.1016/j.leukres.2004.11.024

Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. / Matsuo, Yoshinobu; Drexler, Hans G.; Harashima, Akira; Okochi, Ayumi; Kojima, Kensuke; Asakura, Shoji; Tanimoto, Mitsune; Orita, Kunzo.

In: Leukemia Research, Vol. 29, No. 6, 06.2005, p. 701-710.

Research output: Contribution to journalArticle

Matsuo, Y, Drexler, HG, Harashima, A, Okochi, A, Kojima, K, Asakura, S, Tanimoto, M & Orita, K 2005, 'Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes', Leukemia Research, vol. 29, no. 6, pp. 701-710. https://doi.org/10.1016/j.leukres.2004.11.024
Matsuo, Yoshinobu ; Drexler, Hans G. ; Harashima, Akira ; Okochi, Ayumi ; Kojima, Kensuke ; Asakura, Shoji ; Tanimoto, Mitsune ; Orita, Kunzo. / Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. In: Leukemia Research. 2005 ; Vol. 29, No. 6. pp. 701-710.
@article{1e7d9ffb78df4c0d821c8845882b3a31,
title = "Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes",
abstract = "The two acute myelomonocytic leukemia sister cell lines MOLM-17 and MOLM-18 and the Epstein-Barr-virus positive non-malignant B-lymphoblastoid cell lines (B-LCLs) B422 and B423 were established from the bone marrow sample of a 60-year-old Japanese male in the advanced leukemic phase of refractory anemia with excess of blasts, a subtype of myelodysplastic syndromes (MDS). MOLM-17/-18 are proliferatively responsive to the growth factors present in the culture supernatant of the 5637 cell line. The B-LCLs are constitutively growth factor-independent. MOLM-17 and B422 were established at eight months after the initial diagnosis, while MOLM-18 and B423 were derived from a sample one month later. Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative. MOLM-17/-18 showed immunomarker profiles typical of the myelomonocytic lineage. The karyotype analysis of MOLM-17/-18 revealed various non-random numerical and structural abnormalities including del(5)(q?), -7, der(11)add(11)(p11.2)add(11)(q23), add(17)(p11.2), add(18)(p11.2), -20, -22 as common aberrations. Treatment with tumor necrosis factor-α induced pronounced cellular differentiation of both cell lines into macrophage-like cells. The overall profile of MOLM-17/-18 based on their extensive immunological, cytogenetic and functional characterization suggests that these cell lines together with the paired B-LCLs B422 and B423 may represent scientifically significant in vitro models which could facilitate investigations into the pathobiology of MDS.",
keywords = "AML, Cell line, Differentiation, Leukemia, MDS, TNF-α",
author = "Yoshinobu Matsuo and Drexler, {Hans G.} and Akira Harashima and Ayumi Okochi and Kensuke Kojima and Shoji Asakura and Mitsune Tanimoto and Kunzo Orita",
year = "2005",
month = "6",
doi = "10.1016/j.leukres.2004.11.024",
language = "English",
volume = "29",
pages = "701--710",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes

AU - Matsuo, Yoshinobu

AU - Drexler, Hans G.

AU - Harashima, Akira

AU - Okochi, Ayumi

AU - Kojima, Kensuke

AU - Asakura, Shoji

AU - Tanimoto, Mitsune

AU - Orita, Kunzo

PY - 2005/6

Y1 - 2005/6

N2 - The two acute myelomonocytic leukemia sister cell lines MOLM-17 and MOLM-18 and the Epstein-Barr-virus positive non-malignant B-lymphoblastoid cell lines (B-LCLs) B422 and B423 were established from the bone marrow sample of a 60-year-old Japanese male in the advanced leukemic phase of refractory anemia with excess of blasts, a subtype of myelodysplastic syndromes (MDS). MOLM-17/-18 are proliferatively responsive to the growth factors present in the culture supernatant of the 5637 cell line. The B-LCLs are constitutively growth factor-independent. MOLM-17 and B422 were established at eight months after the initial diagnosis, while MOLM-18 and B423 were derived from a sample one month later. Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative. MOLM-17/-18 showed immunomarker profiles typical of the myelomonocytic lineage. The karyotype analysis of MOLM-17/-18 revealed various non-random numerical and structural abnormalities including del(5)(q?), -7, der(11)add(11)(p11.2)add(11)(q23), add(17)(p11.2), add(18)(p11.2), -20, -22 as common aberrations. Treatment with tumor necrosis factor-α induced pronounced cellular differentiation of both cell lines into macrophage-like cells. The overall profile of MOLM-17/-18 based on their extensive immunological, cytogenetic and functional characterization suggests that these cell lines together with the paired B-LCLs B422 and B423 may represent scientifically significant in vitro models which could facilitate investigations into the pathobiology of MDS.

AB - The two acute myelomonocytic leukemia sister cell lines MOLM-17 and MOLM-18 and the Epstein-Barr-virus positive non-malignant B-lymphoblastoid cell lines (B-LCLs) B422 and B423 were established from the bone marrow sample of a 60-year-old Japanese male in the advanced leukemic phase of refractory anemia with excess of blasts, a subtype of myelodysplastic syndromes (MDS). MOLM-17/-18 are proliferatively responsive to the growth factors present in the culture supernatant of the 5637 cell line. The B-LCLs are constitutively growth factor-independent. MOLM-17 and B422 were established at eight months after the initial diagnosis, while MOLM-18 and B423 were derived from a sample one month later. Immunophenotyping of the first leukemia sample revealed a mixed lineage leukemia immunophenotype with positivity for terminal deoxynucleotidyl transferase (TdT), CD13 and CD19; the second sample revealed solely myeloid characteristics with positivity for CD13, CD41 and CD61, whereas TdT was negative. MOLM-17/-18 showed immunomarker profiles typical of the myelomonocytic lineage. The karyotype analysis of MOLM-17/-18 revealed various non-random numerical and structural abnormalities including del(5)(q?), -7, der(11)add(11)(p11.2)add(11)(q23), add(17)(p11.2), add(18)(p11.2), -20, -22 as common aberrations. Treatment with tumor necrosis factor-α induced pronounced cellular differentiation of both cell lines into macrophage-like cells. The overall profile of MOLM-17/-18 based on their extensive immunological, cytogenetic and functional characterization suggests that these cell lines together with the paired B-LCLs B422 and B423 may represent scientifically significant in vitro models which could facilitate investigations into the pathobiology of MDS.

KW - AML

KW - Cell line

KW - Differentiation

KW - Leukemia

KW - MDS

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=18044396519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044396519&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.11.024

DO - 10.1016/j.leukres.2004.11.024

M3 - Article

C2 - 15863212

AN - SCOPUS:18044396519

VL - 29

SP - 701

EP - 710

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -